{"gene":"PNPLA2","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":2004,"finding":"Desnutrin/PNPLA2 encodes a 486-amino acid protein containing a patatin-like domain; ectopic overexpression in transfected cells increases triglyceride hydrolysis, establishing its lipase function. The fusion protein localizes to the cytoplasm as shown by confocal microscopy of EGFP-tagged desnutrin.","method":"Transfection/overexpression, triglyceride hydrolysis assay, confocal microscopy of EGFP-tagged protein","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct in vitro hydrolysis assay plus localization experiment; founding characterization paper with functional readout","pmids":["15337759"],"is_preprint":false},{"year":2006,"finding":"Loss-of-function mutations in PNPLA2 (truncations affecting the hydrophobic domain but sparing the patatin active site) cause neutral lipid storage disease with myopathy (NLSDM), with triglyceride accumulation mimicked by siRNA knockdown of ATGL, establishing PNPLA2 as the rate-limiting triglyceride hydrolase in multiple tissues.","method":"Patient mutation analysis, siRNA knockdown with lipid accumulation readout","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — human genetics combined with siRNA loss-of-function reproducing the biochemical phenotype; replicated by multiple subsequent mutation reports","pmids":["17187067"],"is_preprint":false},{"year":2011,"finding":"ATGL-catalyzed lipolysis of cellular triglycerides generates lipid ligands required for PPAR-α and PPAR-δ activation; in the heart, ATGL deficiency decreases PGC-1α/β expression, disrupts mitochondrial substrate oxidation and respiration, causing cardiomyopathy that is fully reversed by pharmacological PPAR-α agonist treatment.","method":"Atgl-knockout mouse model, mitochondrial respiration assays, PPAR-α agonist rescue, gene expression analysis","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genetic KO with defined mechanistic readouts and pharmacological rescue; replicated in multiple tissues and labs","pmids":["21857651"],"is_preprint":false},{"year":2011,"finding":"AMPK phosphorylates desnutrin/ATGL at serine 406, increasing its triacylglycerol hydrolase activity. Adipose-specific ATGL ablation converts brown adipose tissue to a WAT-like tissue with impaired thermogenesis and reduced UCP-1/PPARα signaling.","method":"Phosphorylation site mutagenesis, kinase assay, adipose-specific knockout mouse, thermogenesis assay, gene expression","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — site-specific phosphorylation established by mutagenesis and kinase assay; confirmed in vivo with tissue-specific KO","pmids":["21641555"],"is_preprint":false},{"year":2011,"finding":"The minimal catalytically active domain of ATGL extends to leucine 254 (beyond the canonical patatin domain, Ile10–Leu178). This minimal fragment retains triacylglycerol hydrolase activity and can be co-activated by CGI-58 and inhibited by G0S2, and is sufficient for protein–protein interactions with both regulators. A 3D homology model of the minimal domain was generated.","method":"Domain truncation/mutagenesis, in vitro lipase activity assay, protein–protein interaction, homology modeling","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution of activity with truncation mutants plus direct binding assays; single lab but multiple orthogonal methods","pmids":["22039468"],"is_preprint":false},{"year":2010,"finding":"UBXD8 directly binds ATGL on lipid droplets and promotes dissociation of the ATGL co-activator CGI-58, thereby inhibiting ATGL-mediated triacylglycerol hydrolysis and increasing lipid droplet size. UBXD8 recruits p97/VCP to lipid droplets through this interaction.","method":"Co-immunoprecipitation, direct binding assay, LD size measurement, overexpression/knockdown of UBXD8","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct protein binding established, functional consequence on LD lipolysis demonstrated, single lab with multiple orthogonal methods","pmids":["23297223"],"is_preprint":false},{"year":2010,"finding":"G0S2 inhibits ATGL activity and ATGL-mediated lipid droplet degradation. G0S2 binds ATGL independently of its activity state or the presence of CGI-58. CGI-58 co-activation cannot overcome G0S2-mediated inhibition, indicating non-competing regulatory mechanisms.","method":"Co-immunoprecipitation, lipid droplet morphology assay, overexpression studies","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP and functional LD assay in single lab; mechanistic details of non-competition established","pmids":["20676045"],"is_preprint":false},{"year":2010,"finding":"The C-terminal hydrophobic domain of ATGL is required for lipid droplet targeting and CGI-58-independent LD degradation. A deletion mutant lacking this domain fails to localize to LDs and cannot affect their morphology, though CGI-58 co-expression partially rescues this.","method":"Domain deletion mutagenesis, fluorescence localization, lipid droplet morphology assay","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis with localization and functional readout; single lab","pmids":["20676045"],"is_preprint":false},{"year":2009,"finding":"FoxO1 directly binds to two FoxO1-binding sites in the ATGL promoter and transcriptionally activates ATGL expression. Insulin controls nucleo-cytoplasmic shuttling of FoxO1 and regulates its interaction with the endogenous ATGL promoter in adipocytes. FoxO1 knockdown decreases ATGL expression and attenuates lipolysis.","method":"Luciferase reporter assay, ChIP, siRNA knockdown, lipolysis assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — ChIP + reporter assay + knockdown with functional readout; multiple orthogonal methods in single lab","pmids":["19297333"],"is_preprint":false},{"year":2006,"finding":"Insulin downregulates ATGL mRNA via PI3-kinase and p70 S6 kinase pathways. TNF-α downregulates ATGL in parallel with PPARγ reduction, effects attenuated by MEK, PI3K, and mTOR inhibitors. PPARγ transcriptionally activates the ATGL promoter (identified through 5'-flanking region luciferase reporter deletion analysis).","method":"Luciferase reporter assay with promoter deletions, pharmacological inhibitors, adipocyte cell culture","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay with deletion series plus pharmacological dissection; single lab","pmids":["16705060"],"is_preprint":false},{"year":2013,"finding":"Insulin inhibits ATGL transcription through an evolutionarily conserved mTORC1–Egr1 pathway. Egr1 directly inhibits the ATGL promoter in vitro and in cultured adipocytes. The pathway was identified by genetic screen in yeast (Msn4p/Tor1 axis as ATGL ortholog regulator) and validated in mammalian cells.","method":"Yeast genetic screen, Egr1 promoter binding assay, adipocyte knockdown/overexpression, high-fat-diet mouse model","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genetic epistasis screen + direct promoter binding + in vivo validation; multiple orthogonal methods across organisms","pmids":["23858058"],"is_preprint":false},{"year":2011,"finding":"SIRT1 controls ATGL transcription by deacetylating FoxO1, thereby regulating FoxO1's functional activity at the ATGL promoter. SIRT1 knockdown decreases ATGL expression and attenuates lipolysis in adipocytes.","method":"shRNA knockdown, lipolysis assay, dominant-negative AMPK cell line, gene expression analysis","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — shRNA knockdown with functional and transcriptional readouts; single lab, mechanistic link to FoxO1 acetylation established","pmids":["21743036"],"is_preprint":false},{"year":2015,"finding":"ATGL-catalyzed lipolysis positively regulates SIRT1 deacetylase activity to promote PGC-1α signaling and oxidative metabolism, independent of changes in NAD+. ATGL mediates β-adrenergic signaling effects on SIRT1 activity and PPAR-α target gene expression, establishing SIRT1 as a critical node linking lipolysis to transcriptional regulation of oxidative metabolism.","method":"ATGL overexpression/knockdown, SIRT1 deacetylase activity assay, gene expression, β-adrenergic stimulation","journal":"Diabetes","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — enzymatic activity assay plus genetic manipulation; single lab","pmids":["25614670"],"is_preprint":false},{"year":2013,"finding":"Desnutrin/ATGL ablation in pancreatic β-cells impairs glucose-stimulated insulin secretion (GSIS) by reducing lipolysis-derived PPARδ ligands, which are required for normal mitochondrial oxidative gene expression and ATP production. Synthetic PPARδ (but not PPARα) agonist restores GSIS in β-cell-specific KO mice.","method":"β-cell-specific Atgl KO, GSIS assay, mitochondrial respiration, PPARδ agonist rescue, adenoviral ATGL re-expression","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — tissue-specific KO, rescue with specific agonist, adenoviral reconstitution confirming specificity; multiple orthogonal methods","pmids":["24268737"],"is_preprint":false},{"year":2014,"finding":"FSP27 (amino acids 120–220) directly interacts with ATGL to inhibit its lipolytic function and promote triglyceride storage in human adipocytes. FSP27 depletion increases lipolysis and inhibits insulin signaling via reduced AKT phosphorylation, which is rescued by ATGL depletion or exogenous FSP27 expression.","method":"Co-immunoprecipitation, domain mapping, siRNA knockdown, lipolysis assay, insulin signaling assay in human adipocytes","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct binding domain mapped, functional consequences in human cells with multiple orthogonal methods","pmids":["24627478"],"is_preprint":false},{"year":2011,"finding":"GBF1 (Golgi Brefeldin A resistance factor 1) and ATGL interact directly; multiple contact sites exist: the C-terminal region of ATGL interacts with N-terminal (including Sec7) domains of GBF1, while the patatin (lipase) domain of ATGL interacts with GBF1 HDS1 and HDS2 C-terminal domains. This interaction contributes to ATGL delivery to lipid droplets via a GBF1/Arf1/COPI trafficking pathway.","method":"Yeast two-hybrid, co-immunoprecipitation, direct protein binding, subcellular localization of GBF1 domain fragments","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid + Co-IP + direct binding; single lab with multiple orthogonal methods","pmids":["21789191"],"is_preprint":false},{"year":2012,"finding":"Perilipin 1, but not FSP27, directly inhibits ATGL triacylglycerol hydrolase activity in vitro and attenuates CGI-58-dependent co-activation of ATGL. Perilipin 1 is required for isoproterenol-stimulated translocation of ATGL to lipid droplets, while FSP27 constitutively limits LD presence of ATGL.","method":"In vitro triacylglycerol hydrolase assay, siRNA knockdown, overexpression, LD translocation imaging","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro enzymatic assay with direct inhibition demonstrated plus cell-based localization studies; single lab, multiple orthogonal methods","pmids":["23204327"],"is_preprint":false},{"year":2013,"finding":"In skeletal muscle, contraction stimulation increases the ATGL–CGI-58 interaction by 128%. ATGL interacts with PLIN2, PLIN3, and PLIN5 at rest; the PLIN2–ATGL interaction decreases 21% with contraction. PLIN2 does not interact with CGI-58, suggesting PLINs differentially regulate ATGL–CGI-58 association.","method":"Co-immunoprecipitation from rat skeletal muscle at rest vs. electrically stimulated contraction","journal":"American journal of physiology. Regulatory, integrative and comparative physiology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP in physiologically relevant context replicated for multiple interaction partners; single lab","pmids":["23408028"],"is_preprint":false},{"year":2016,"finding":"In vivo, adipose-specific knockout of both AMPK α1 and α2 subunits abolishes phosphorylation of desnutrin/ATGL at S406, reducing triacylglycerol hydrolase activity and lowering basal lipolysis, providing direct in vivo evidence that AMPK phosphorylates and activates ATGL. AMPK-ASKO mice also show defective HSL phosphorylation at S565.","method":"Adipose-specific AMPK double-knockout mouse, phosphorylation analysis, TAG hydrolase activity assay, adipocyte lipolysis assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic KO confirming kinase–substrate relationship; replicates and extends prior in vitro phosphorylation finding","pmids":["27185873"],"is_preprint":false},{"year":2022,"finding":"ATGL catalyzes FAHFA (fatty acid esters of hydroxy fatty acids) biosynthesis via a transacylation reaction, esterifying a hydroxy fatty acid with a fatty acid from triglyceride or diglyceride. Catalytically dead ATGL fails to increase FAHFA production; chemical inhibition or genetic deletion of Atgl reduces FAHFA and FAHFA-TG levels by 80–90% in adipose tissue. ATGL transacylase activity is present in human adipose tissue.","method":"Recombinant ATGL in vitro transacylation assay, catalytic dead mutant, chemical inhibition (atglistatin), adipose-specific Atgl KO mouse, chemical biology/proteomics","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with recombinant protein + mutagenesis + genetic KO + pharmacological inhibition; replicated in human tissue","pmids":["35676490"],"is_preprint":false},{"year":2024,"finding":"zDHHC11 S-acylates ATGL at cysteine 15, and this modification is required for ATGL catalytic activity. Preventing S-acylation (C15 mutation) renders ATGL catalytically inactive despite proper lipid droplet localization, causing LD accumulation and defective lipolysis/lipophagy. Overexpression of zDHHC11 reduces LD size; its elimination enlarges LDs.","method":"Site-directed mutagenesis (C15), S-acylation assay, lipolysis assay, LD imaging, overexpression/knockdown in hepatocytes and mice","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis of acylation site with enzymatic activity readout and in vivo validation; single lab with multiple orthogonal methods","pmids":["39143266"],"is_preprint":false},{"year":2024,"finding":"PNPLA3(148M) promotes hepatic steatosis as a gain-of-function by accumulating on lipid droplets and sequestering ABHD5 (CGI-58) away from ATGL, thereby limiting ATGL-mediated TG hydrolysis. ABHD5 activates both PNPLA3 and ATGL in vitro. PNPLA3(148M)-associated inhibition of TG hydrolysis requires ATGL expression and LD localization of PNPLA3. Overexpression of ABHD5 reversed hepatic steatosis in Pnpla3M/M mice.","method":"NanoBiT complementation assay, in vitro TG hydrolysis with purified recombinant proteins, liver-specific Atgl-KO mice, adenoviral/AAV expression, immunocytochemistry","journal":"Journal of hepatology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro reconstitution with purified proteins + NanoBiT interaction assay + genetic mouse models; single lab with multiple orthogonal methods","pmids":["39550037"],"is_preprint":false},{"year":2024,"finding":"Intracellular glucose depletion lowers Golgi PtdIns4P levels, reducing assembly of the CUL7FBXW8 E3 ubiquitin ligase complex in the Golgi, which decreases polyubiquitylation of ATGL and enhances ATGL-driven lipolysis. This constitutes a cell-intrinsic glucose-sensing mechanism controlling FA liberation from lipid droplets.","method":"PtdIns4P manipulation, CUL7FBXW8 assembly assay, ATGL ubiquitylation assay, genetic/pharmacological manipulation in mouse models and ex vivo human liver perfusion","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — biochemical ubiquitylation assay + genetic manipulation in vivo + human tissue validation; single lab with multiple orthogonal approaches","pmids":["38561547"],"is_preprint":false},{"year":2019,"finding":"PEDF promotes proteasomal degradation of ATGL via COP1-mediated polyubiquitylation. PEDF enhances nuclear import of ATGL for its subsequent proteasomal degradation in the nucleus. This COP1–ATGL axis controls hepatocyte lipid accumulation and mobilization.","method":"Co-immunoprecipitation, proteasome inhibitor assay, nuclear fractionation, overexpression/knockdown of COP1 and PEDF in hepatocytes","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP + fractionation + functional lipid assay; single lab, mechanistic pathway defined","pmids":["30926171"],"is_preprint":false},{"year":2017,"finding":"LDAH (lipid droplet-associated hydrolase) enhances polyubiquitination and proteasomal degradation of ATGL, thereby increasing TAG levels and LD size. Co-expression of ATGL reverses the LD phenotype induced by LDAH overexpression.","method":"Ubiquitination assay, pulse-chase, overexpression/knockdown in HEK293 cells, TAG measurement, LD morphology","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — ubiquitination assay and functional rescue; single lab","pmids":["28578400"],"is_preprint":false},{"year":2016,"finding":"G0S2 protein stability is regulated by K48-linked polyubiquitination at lysine 25; mutation of K25 abolishes ubiquitination and stabilizes G0S2. ATGL expression stabilizes G0S2 protein (but not mRNA); G0S2 protein levels are reduced in adipose tissue of ATGL-deficient mice, confirming ATGL's role in G0S2 stabilization.","method":"Ubiquitination assay, site-directed mutagenesis (K25), Atgl-KO mouse tissue analysis, protein stability assay","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — mutagenesis of ubiquitination site plus in vivo KO confirmation; single lab","pmids":["27248498"],"is_preprint":false},{"year":2008,"finding":"ATGL protein is expressed in human skeletal muscle exclusively in type I (oxidative) muscle fibers, as established by immunohistochemistry and immunofluorescence with fiber-type markers.","method":"Immunohistochemistry, immunofluorescence, fiber-type co-staining in human vastus lateralis biopsies","journal":"Histochemistry and cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct localization experiment in human tissue; single lab, single method but clear result","pmids":["18224330"],"is_preprint":false},{"year":2014,"finding":"Hepatic ATGL channels hydrolyzed fatty acids preferentially to β-oxidation and induces PPAR-α signaling independent of liver fatty acid binding protein (L-FABP). L-FABP deletion does not impair ATGL-mediated FA channeling to mitochondria or PPAR-α target gene regulation.","method":"Adenovirus-mediated ATGL knockdown/overexpression in WT and L-FABP KO mice, primary hepatocyte oxidation assays, serum β-hydroxybutyrate measurement","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis (double KO) with functional metabolic readout; single lab","pmids":["24610891"],"is_preprint":false},{"year":2020,"finding":"ATGL cooperates with ABHD5/CGI-58 to mobilize lipids from lipid droplets for hepatitis C virus assembly and lipoprotein morphogenesis. ABHD5 residues critical for ATGL activation, when grafted onto the non-activating paralog ABHD4, restored both pro-viral and lipolytic functions, defining the ABHD5–ATGL protein interface required for co-lipase activity.","method":"ATGL expression modulation, chemical inhibition (atglistatin), ABHD5 chimeric protein engineering, co-immunoprecipitation, lipid droplet lipolysis assay, viral production assay","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — chimeric protein rescue experiment defining interaction interface + multiple orthogonal methods; single lab","pmids":["32542055"],"is_preprint":false},{"year":2022,"finding":"STX11 directly binds ATGL via its C-terminal domain interacting with the patatin domain-containing segment of ATGL, preventing ATGL translocation to lipid droplets by recruiting ATGL to the ER. STX11 deficiency in hepatocytes promotes lipolysis via ATGL-SIRT1 signaling and enhances lipophagy.","method":"Co-immunoprecipitation, domain mapping, subcellular localization imaging, overexpression/knockdown, lipid hydrolysis assay","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — direct binding with domain mapping and functional localization consequence; single lab","pmids":["35372814"],"is_preprint":false},{"year":2019,"finding":"In the intestine, ATGL/CGI-58 specifically catalyzes hydrolysis of a lipid storage pool derived from basolateral (blood-side) lipid uptake/secretion–re-uptake cycle, but is not involved in providing substrates for chylomicron synthesis from dietary lipids.","method":"Intestine-specific ATGL/CGI-58 double KO mice, dietary lipid challenge, lipid droplet accumulation analysis","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — tissue-specific double KO with defined phenotypic dissection of two lipid pools; single lab","pmids":["31412256"],"is_preprint":false},{"year":2014,"finding":"HCV core protein localizes to lipid droplet surfaces and inhibits ATGL-mediated lipolysis without directly interacting with ATGL or CGI-58, but unexpectedly increases ATGL–CGI-58 interaction and recruitment of both to LDs. ATGL-KO MEFs expressing core show no decrease in TG degradation, confirming core acts through ATGL.","method":"Co-immunoprecipitation, ATGL-KO mouse embryonic fibroblasts, ex vivo LD TG hydrolysis assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO epistasis plus Co-IP and biochemical assay; single lab","pmids":["25381252"],"is_preprint":false},{"year":2017,"finding":"Combined adipose-specific deficiency of ATGL and HSL (DAKO mice) causes fully penetrant liposarcoma in all mice by 11–14 months, establishing a genetic epistatic interaction between Pnpla2 and Lipe; this phenotype does not occur with either single knockout alone.","method":"Double adipose-specific KO mouse (epistasis), tumor histology, transcriptome analysis","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — fully penetrant genetic epistasis established in vivo with clear phenotype; double vs. single KO controls","pmids":["28459858"],"is_preprint":false},{"year":2019,"finding":"When HSL is deficient, ATGL functions as a transacylase, transferring an acyl group from one diacylglycerol to another, forming a triglyceride plus a monoglyceride. This ATGL transacylase activity was abolished by a specific ATGL inhibitor, revealing a previously unknown physiological redundancy between ATGL and HSL.","method":"Radiolabeled DG incubation with HSL-deficient lipid droplet fractions, ATGL-specific inhibitor (atglistatin) treatment","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — biochemical transacylase assay with specific inhibitor control; single lab","pmids":["31035700"],"is_preprint":false},{"year":2016,"finding":"ATGL overexpression in ATGL-deficient hepatocellular carcinoma cells activates PPAR-α/p300-mediated acetylation and accumulation of p53 protein (without altering p53 mRNA), rewiring metabolism toward oxidative fatty acid metabolism and reducing glucose uptake/glycolysis.","method":"ATGL overexpression in HCC cell lines, p53 knockdown/KO epistasis, PPAR-α/p300 inhibition, metabolic assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis experiments with p53 KO; multiple pathway readouts; single lab","pmids":["30367149"],"is_preprint":false},{"year":2021,"finding":"ATGL-mediated lipolysis regulates glucose uptake in adipocytes via TXNIP stability: cAMP-induced ATGL activation promotes TXNIP degradation, selectively inducing GLUT1 surface localization and glucose uptake. ATGL knockdown prevents cAMP-dependent TXNIP degradation and reduces glucose uptake; this mechanism was validated in human primary adipocytes.","method":"siRNA knockdown, ATGL overexpression, TXNIP stability assay, GLUT1 surface localization, glucose uptake assay in 3T3-L1 and human primary adipocytes","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway defined with knockdown and overexpression, validated in human cells; single lab","pmids":["33508319"],"is_preprint":false},{"year":2016,"finding":"ATGL and CGI-58 are co-resident on lipid droplets in rat hepatic stellate cells (HSC-T6). Rat ATGL co-activated by rat CGI-58 efficiently hydrolyzes both triacylglycerols and retinyl esters in vitro.","method":"LD proteomics, LD isolation, in vitro hydrolase activity assay with rATGL and rCGI-58","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — in vitro enzymatic reconstitution + LD proteomics; single lab","pmids":["26330055"],"is_preprint":false}],"current_model":"PNPLA2/ATGL is the rate-limiting triacylglycerol (TG) lipase that initiates intracellular lipolysis via a patatin-domain catalytic dyad (Ser47/Asp166) requiring a minimal active domain extending to Leu254; its lipase activity is co-activated by CGI-58/ABHD5 (released from perilipin 1 upon β-adrenergic stimulation), inhibited by G0S2 and FSP27, regulated by AMPK-mediated phosphorylation at S406, and modulated post-translationally by S-acylation at Cys15 (by zDHHC11), ubiquitin-proteasomal degradation (via COP1, CUL7FBXW8 E3 ligase, LDAH), and PEDF-driven nuclear import; ATGL delivers lipid ligands to PPAR-α/δ to activate PGC-1α/β and mitochondrial oxidative metabolism, generates FAHFAs via transacylation, controls insulin secretion in β-cells via PPARδ, regulates glucose uptake through TXNIP stability, and when absent causes lethal cardiomyopathy, lipid storage myopathy (NLSDM), and impaired thermogenesis."},"narrative":{"mechanistic_narrative":"PNPLA2 (desnutrin/ATGL) is the rate-limiting triacylglycerol hydrolase that initiates intracellular lipolysis, mobilizing fatty acids from lipid droplets via a patatin-like domain whose minimal catalytically active fragment extends beyond the canonical patatin region to Leu254 [PMID:15337759, PMID:17187067, PMID:22039468]. Loss-of-function mutations sparing the active site but truncating the hydrophobic domain cause neutral lipid storage disease with myopathy (NLSDM), and ATGL deficiency drives lethal cardiomyopathy that is reversed by PPAR-α agonism, because ATGL-liberated fatty acids serve as ligands that activate PPAR-α/δ and PGC-1α/β-driven mitochondrial oxidative metabolism [PMID:17187067, PMID:21857651]. Beyond canonical hydrolysis, ATGL catalyzes transacylation reactions that generate FAHFA lipid species and, when HSL is absent, form triglyceride from diacylglycerol [PMID:35676490, PMID:31035700]. Its activity is tightly governed: co-activated by CGI-58/ABHD5 through a defined protein interface and inhibited by G0S2, FSP27, and perilipin 1 [PMID:22039468, PMID:20676045, PMID:24627478, PMID:23204327, PMID:32542055], activated by AMPK phosphorylation at S406 [PMID:21641555, PMID:27185873], and dependent on zDHHC11-mediated S-acylation at Cys15 for catalysis [PMID:39143266]. ATGL is targeted to lipid droplets through its C-terminal hydrophobic domain and GBF1/Arf1/COPI trafficking, and is restrained by ER-tethering via STX11 and by ubiquitin-proteasomal turnover through CUL7ᶠᵇˣʷ⁸, COP1/PEDF, and LDAH [PMID:20676045, PMID:21789191, PMID:38561547, PMID:30926171, PMID:28578400, PMID:35372814]. Transcriptionally, ATGL is induced by FoxO1 (deacetylated by SIRT1) and PPARγ and repressed by insulin via mTORC1–Egr1 signaling [PMID:19297333, PMID:16705060, PMID:23858058, PMID:21743036]. Through these outputs ATGL links lipolysis to oxidative metabolism via SIRT1–PGC-1α, controls glucose-stimulated insulin secretion via PPARδ in β-cells, and regulates adipocyte glucose uptake by promoting TXNIP degradation [PMID:25614670, PMID:24268737, PMID:33508319].","teleology":[{"year":2004,"claim":"Established that PNPLA2 encodes a patatin-domain protein with intrinsic triglyceride hydrolase activity, defining the gene product as a lipase.","evidence":"Ectopic overexpression with TG hydrolysis assay and EGFP localization in transfected cells","pmids":["15337759"],"confidence":"High","gaps":["Did not establish in vivo physiological role","Catalytic residues and regulators unidentified"]},{"year":2006,"claim":"Showed PNPLA2 is the rate-limiting TG hydrolase in vivo and that its loss causes a human disease, connecting biochemistry to pathology.","evidence":"Patient mutation analysis (NLSDM) plus siRNA knockdown with lipid accumulation; insulin/TNF-α promoter regulation by reporter assay","pmids":["17187067","16705060"],"confidence":"High","gaps":["Downstream metabolic consequences of fatty-acid liberation not defined","Co-activators and inhibitors not yet identified"]},{"year":2009,"claim":"Identified transcriptional control of ATGL by FoxO1, explaining hormonal regulation of lipolytic capacity.","evidence":"ChIP, luciferase reporter, siRNA knockdown and lipolysis assay in adipocytes","pmids":["19297333"],"confidence":"High","gaps":["Did not address post-translational regulation","Interplay with other transcription factors unresolved"]},{"year":2010,"claim":"Defined direct protein inhibitors (G0S2, UBXD8) and the C-terminal LD-targeting domain, establishing that ATGL activity and localization are governed by distinct interactions.","evidence":"Co-IP, direct binding, domain deletion mutagenesis and LD morphology assays","pmids":["20676045","23297223"],"confidence":"Medium","gaps":["Structural basis of inhibitor binding not resolved","Single-lab Co-IP for some interactions"]},{"year":2011,"claim":"Connected ATGL-derived lipid ligands to PPAR/PGC-1α-driven mitochondrial metabolism and defined AMPK phosphorylation at S406 as an activating modification, explaining the cardiomyopathy and thermogenic phenotypes.","evidence":"Atgl-KO and adipose-specific KO mice, mitochondrial respiration, PPAR-α agonist rescue, phosphosite mutagenesis and kinase assay","pmids":["21857651","21641555"],"confidence":"High","gaps":["Identity of the specific ligand lipid species not defined","How phosphorylation alters catalysis mechanistically unclear"]},{"year":2011,"claim":"Mapped the minimal catalytic domain to Leu254 and showed it suffices for CGI-58 co-activation and G0S2 inhibition, localizing regulation to a defined region.","evidence":"Truncation mutagenesis, in vitro lipase assay, binding assay, homology modeling","pmids":["22039468"],"confidence":"High","gaps":["No experimental crystal structure","Role of the C-terminal region in vivo not fully resolved"]},{"year":2011,"claim":"Linked SIRT1 deacetylation of FoxO1 to ATGL transcription, integrating energy/NAD+ status with lipolytic gene expression.","evidence":"shRNA knockdown, lipolysis and gene expression assays in adipocytes","pmids":["21743036"],"confidence":"Medium","gaps":["Direct demonstration of FoxO1 acetylation at the ATGL promoter limited","Single-lab study"]},{"year":2011,"claim":"Identified GBF1/Arf1/COPI trafficking as a route delivering ATGL to lipid droplets, defining a transport mechanism.","evidence":"Yeast two-hybrid, Co-IP, direct binding and localization of GBF1 domain fragments","pmids":["21789191"],"confidence":"Medium","gaps":["Physiological contribution of this route versus C-terminal targeting unquantified","Single-lab interaction data"]},{"year":2012,"claim":"Distinguished perilipin 1 as a direct in vitro inhibitor and obligate translocation factor versus FSP27's constitutive restriction, refining the LD-surface regulatory hierarchy.","evidence":"In vitro TAG hydrolase assay, siRNA, LD translocation imaging","pmids":["23204327"],"confidence":"High","gaps":["Structural basis of perilipin1–ATGL inhibition not defined"]},{"year":2013,"claim":"Extended the regulatory network with FSP27 direct binding, mTORC1–Egr1 insulin repression, and a β-cell PPARδ lipolytic-signaling axis controlling insulin secretion.","evidence":"Co-IP/domain mapping, yeast screen with promoter binding, β-cell-specific KO with PPARδ agonist rescue and contraction-state muscle Co-IP","pmids":["24627478","23858058","24268737","23408028"],"confidence":"High","gaps":["Tissue-specific differences in regulator usage not fully mapped","Some interaction data from single labs"]},{"year":2015,"claim":"Established SIRT1 as a node downstream of ATGL lipolysis driving PGC-1α/PPAR-α oxidative transcription independent of NAD+, clarifying signal-to-transcription coupling.","evidence":"ATGL gain/loss, SIRT1 deacetylase activity assay, β-adrenergic stimulation","pmids":["25614670"],"confidence":"Medium","gaps":["Mechanism by which a lipid product activates SIRT1 unresolved","Single-lab study"]},{"year":2016,"claim":"Provided in vivo proof that AMPK phosphorylates and activates ATGL at S406 and defined reciprocal ATGL-dependent G0S2 protein stabilization, closing loops in activity regulation.","evidence":"Adipose-specific AMPK double-KO mice, phosphorylation and TAG hydrolase assays; G0S2 K25 ubiquitination mutagenesis with Atgl-KO tissue","pmids":["27185873","27248498"],"confidence":"High","gaps":["Whether AMPK acts directly on ATGL in vivo versus via other kinases not fully excluded"]},{"year":2017,"claim":"Defined ubiquitin-proteasomal turnover (LDAH-enhanced) and a tumor-suppressive epistasis with HSL whose dual loss causes liposarcoma, linking lipolytic capacity to proliferation control.","evidence":"Ubiquitination/pulse-chase assays; adipose-specific ATGL/HSL double-KO mouse with tumor histology","pmids":["28578400","28459858"],"confidence":"High","gaps":["Mechanism linking lipid accumulation to tumorigenesis not defined","E3 ligase for LDAH-driven turnover not identified here"]},{"year":2019,"claim":"Revealed ATGL transacylase activity (DG-to-TG when HSL is absent), nuclear COP1/PEDF degradation, and tissue-specific intestinal substrate pools, broadening its enzymatic and regulatory repertoire.","evidence":"Radiolabeled DG transacylation with inhibitor control; Co-IP and nuclear fractionation; intestine-specific double KO","pmids":["31035700","30926171","31412256"],"confidence":"Medium","gaps":["Physiological significance of transacylase activity under normal HSL unclear","Nuclear degradation pathway from single lab"]},{"year":2021,"claim":"Connected ATGL lipolysis to glucose handling by showing it promotes TXNIP degradation to enhance GLUT1-mediated glucose uptake, expanding its role beyond fatty-acid metabolism.","evidence":"Knockdown/overexpression, TXNIP stability and GLUT1 surface assays in mouse and human adipocytes","pmids":["33508319"],"confidence":"Medium","gaps":["Signal linking lipolysis to TXNIP turnover not fully defined","Single-lab mechanism"]},{"year":2022,"claim":"Established ATGL as the principal biosynthetic enzyme for FAHFAs via transacylation, identifying a signaling-lipid output of the lipase.","evidence":"Recombinant ATGL in vitro transacylation, catalytic-dead mutant, atglistatin, adipose-specific KO, validated in human tissue","pmids":["35676490"],"confidence":"High","gaps":["Regulation of hydrolase-versus-transacylase partitioning unclear","Acceptor/donor specificity in vivo not fully mapped"]},{"year":2024,"claim":"Identified S-acylation at Cys15 by zDHHC11 as essential for catalysis and a Golgi PtdIns4P/CUL7FBXW8 glucose-sensing ubiquitylation circuit, plus a PNPLA3(148M) mechanism that sequesters ABHD5, defining post-translational and competitive controls on lipolysis.","evidence":"C15 mutagenesis with acylation/lipolysis assays; PtdIns4P/CUL7FBXW8 assembly and ubiquitylation assays with human liver; NanoBiT and purified-protein hydrolysis with Atgl-KO mice","pmids":["39143266","38561547","39550037"],"confidence":"High","gaps":["How Cys15 acylation alters the catalytic mechanism not structurally defined","Interplay among competing ubiquitin ligases not resolved"]},{"year":null,"claim":"An integrated structural and quantitative model of how the multiple competing co-activators, inhibitors, and post-translational modifications set ATGL output in each tissue remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No experimental high-resolution structure of full-length ATGL or its regulatory complexes","Relative in vivo weighting of CGI-58, G0S2, perilipin1, FSP27, acylation, and degradation not quantified","Determinants of hydrolase-versus-transacylase activity unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,1,4,16,36]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[19,33]}],"localization":[{"term_id":"GO:0005811","term_label":"lipid droplet","supporting_discovery_ids":[5,7,16,20,36]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[29]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[23]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,2,19]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,12,13,35]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[20,22,23,24]}],"complexes":[],"partners":["ABHD5","G0S2","CIDEC","PLIN1","UBXD8","GBF1","STX11","PNPLA3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q96AD5","full_name":"Patatin-like phospholipase domain-containing protein 2","aliases":["Adipose triglyceride lipase","Calcium-independent phospholipase A2-zeta","iPLA2-zeta","Desnutrin","Pigment epithelium-derived factor receptor","PEDF-R","TTS2.2","Transport-secretion protein 2","TTS2"],"length_aa":504,"mass_kda":55.3,"function":"Catalyzes the initial step in triglyceride hydrolysis in adipocyte and non-adipocyte lipid droplets (PubMed:15364929, PubMed:15550674, PubMed:16150821, PubMed:16239926, PubMed:17603008, PubMed:34903883). Exhibits a strong preference for the hydrolysis of long-chain fatty acid esters at the sn-2 position of the glycerol backbone and acts coordinately with LIPE/HLS and DGAT2 within the lipolytic cascade (By similarity). Also possesses acylglycerol transacylase and phospholipase A2 activities (PubMed:15364929, PubMed:17032652, PubMed:17603008). Transfers fatty acid from triglyceride to retinol, hydrolyzes retinylesters, and generates 1,3-diacylglycerol from triglycerides (PubMed:17603008). Regulates adiposome size and may be involved in the degradation of adiposomes (PubMed:16239926). Catalyzes the formation of an ester bond between hydroxy fatty acids and fatty acids derived from triglycerides or diglycerides to generate fatty acid esters of hydroxy fatty acids (FAHFAs) in adipocytes (PubMed:35676490). Acts antagonistically with LDAH in regulation of cellular lipid stores (PubMed:28578400). Inhibits LDAH-stimulated lipid droplet fusion (PubMed:28578400). May play an important role in energy homeostasis (By similarity). May play a role in the response of the organism to starvation, enhancing hydrolysis of triglycerides and providing free fatty acids to other tissues to be oxidized in situations of energy depletion (By similarity)","subcellular_location":"Lipid droplet; Cell membrane; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q96AD5/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PNPLA2","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000177666","cell_line_id":"CID001821","localizations":[{"compartment":"vesicles","grade":3}],"interactors":[],"url":"https://opencell.sf.czbiohub.org/target/CID001821","total_profiled":1310},"omim":[{"mim_id":"613248","title":"PERILIPIN 5; PLIN5","url":"https://www.omim.org/entry/613248"},{"mim_id":"610717","title":"NEUTRAL LIPID STORAGE DISEASE WITH MYOPATHY; NLSDM","url":"https://www.omim.org/entry/610717"},{"mim_id":"609567","title":"PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 3; PNPLA3","url":"https://www.omim.org/entry/609567"},{"mim_id":"609059","title":"PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 2; PNPLA2","url":"https://www.omim.org/entry/609059"},{"mim_id":"606416","title":"NLR FAMILY, PYRIN DOMAIN-CONTAINING 3; NLRP3","url":"https://www.omim.org/entry/606416"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Lipid droplets","reliability":"Enhanced"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"adipose tissue","ntpm":487.2},{"tissue":"breast","ntpm":357.1}],"url":"https://www.proteinatlas.org/search/PNPLA2"},"hgnc":{"alias_symbol":["desnutrin","TTS-2.2","ATGL","FP17548","iPLA2zeta"],"prev_symbol":[]},"alphafold":{"accession":"Q96AD5","domains":[{"cath_id":"-","chopping":"10-260_297-313","consensus_level":"high","plddt":90.0141,"start":10,"end":313},{"cath_id":"-","chopping":"316-386","consensus_level":"medium","plddt":78.8575,"start":316,"end":386}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96AD5","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q96AD5-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q96AD5-F1-predicted_aligned_error_v6.png","plddt_mean":72.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PNPLA2","jax_strain_url":"https://www.jax.org/strain/search?query=PNPLA2"},"sequence":{"accession":"Q96AD5","fasta_url":"https://rest.uniprot.org/uniprotkb/Q96AD5.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q96AD5/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96AD5"}},"corpus_meta":[{"pmid":"21857651","id":"PMC_21857651","title":"ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1.","date":"2011","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21857651","citation_count":649,"is_preprint":false},{"pmid":"15337759","id":"PMC_15337759","title":"Desnutrin, an adipocyte gene encoding a novel patatin domain-containing protein, is induced by fasting and glucocorticoids: ectopic expression of desnutrin increases triglyceride hydrolysis.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15337759","citation_count":502,"is_preprint":false},{"pmid":"21641555","id":"PMC_21641555","title":"Desnutrin/ATGL is regulated by AMPK and is required for a brown adipose phenotype.","date":"2011","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/21641555","citation_count":428,"is_preprint":false},{"pmid":"17187067","id":"PMC_17187067","title":"The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy.","date":"2006","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17187067","citation_count":383,"is_preprint":false},{"pmid":"19401457","id":"PMC_19401457","title":"Neutral lipid storage disease: genetic disorders caused by mutations in adipose triglyceride lipase/PNPLA2 or CGI-58/ABHD5.","date":"2009","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19401457","citation_count":238,"is_preprint":false},{"pmid":"27185873","id":"PMC_27185873","title":"AMPK Phosphorylates Desnutrin/ATGL and Hormone-Sensitive Lipase To Regulate Lipolysis and Fatty Acid Oxidation within Adipose Tissue.","date":"2016","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27185873","citation_count":228,"is_preprint":false},{"pmid":"20107043","id":"PMC_20107043","title":"Dysregulation of lipolysis and lipid metabolism in visceral and subcutaneous adipocytes by high-fat diet: role of ATGL, HSL, and AMPK.","date":"2010","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/20107043","citation_count":219,"is_preprint":false},{"pmid":"23297223","id":"PMC_23297223","title":"Spatial regulation of UBXD8 and p97/VCP controls ATGL-mediated lipid droplet turnover.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23297223","citation_count":195,"is_preprint":false},{"pmid":"19297333","id":"PMC_19297333","title":"FoxO1 controls insulin-dependent adipose triglyceride lipase (ATGL) expression and lipolysis in adipocytes.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19297333","citation_count":188,"is_preprint":false},{"pmid":"29764424","id":"PMC_29764424","title":"Long non-coding RNA NEAT1-modulated abnormal lipolysis via ATGL drives hepatocellular carcinoma proliferation.","date":"2018","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29764424","citation_count":175,"is_preprint":false},{"pmid":"16705060","id":"PMC_16705060","title":"The adipose tissue triglyceride lipase ATGL/PNPLA2 is downregulated by insulin and TNF-alpha in 3T3-L1 adipocytes and is a target for transactivation by PPARgamma.","date":"2006","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16705060","citation_count":168,"is_preprint":false},{"pmid":"25614670","id":"PMC_25614670","title":"ATGL-catalyzed lipolysis regulates SIRT1 to control PGC-1α/PPAR-α signaling.","date":"2015","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/25614670","citation_count":165,"is_preprint":false},{"pmid":"19050316","id":"PMC_19050316","title":"Prolonged AICAR-induced AMP-kinase activation promotes energy dissipation in white adipocytes: novel mechanisms integrating HSL and ATGL.","date":"2008","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/19050316","citation_count":164,"is_preprint":false},{"pmid":"21743036","id":"PMC_21743036","title":"SIRT1 controls lipolysis in adipocytes via FOXO1-mediated expression of ATGL.","date":"2011","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/21743036","citation_count":155,"is_preprint":false},{"pmid":"30367950","id":"PMC_30367950","title":"Of mice and men: The physiological role of adipose triglyceride lipase (ATGL).","date":"2018","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/30367950","citation_count":141,"is_preprint":false},{"pmid":"23858058","id":"PMC_23858058","title":"Insulin inhibits lipolysis in adipocytes via the evolutionarily conserved mTORC1-Egr1-ATGL-mediated pathway.","date":"2013","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23858058","citation_count":132,"is_preprint":false},{"pmid":"35676490","id":"PMC_35676490","title":"ATGL is a biosynthetic enzyme for fatty acid esters of hydroxy fatty acids.","date":"2022","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/35676490","citation_count":103,"is_preprint":false},{"pmid":"24268737","id":"PMC_24268737","title":"Desnutrin/ATGL activates PPARδ to promote mitochondrial function for insulin secretion in islet β cells.","date":"2013","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24268737","citation_count":103,"is_preprint":false},{"pmid":"24627478","id":"PMC_24627478","title":"Fat-specific protein 27 (FSP27) interacts with adipose triglyceride lipase (ATGL) to regulate lipolysis and insulin sensitivity in human adipocytes.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24627478","citation_count":100,"is_preprint":false},{"pmid":"20676045","id":"PMC_20676045","title":"Differential control of ATGL-mediated lipid droplet degradation by CGI-58 and G0S2.","date":"2010","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/20676045","citation_count":97,"is_preprint":false},{"pmid":"22984285","id":"PMC_22984285","title":"Adipose triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL) deficiencies affect expression of lipolytic activities in mouse adipose tissues.","date":"2012","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/22984285","citation_count":97,"is_preprint":false},{"pmid":"27759039","id":"PMC_27759039","title":"LncRNA SRA promotes hepatic steatosis through repressing the expression of adipose triglyceride lipase (ATGL).","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27759039","citation_count":96,"is_preprint":false},{"pmid":"35675775","id":"PMC_35675775","title":"ATGL-dependent white adipose tissue lipolysis controls hepatocyte PPARα activity.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/35675775","citation_count":86,"is_preprint":false},{"pmid":"22374972","id":"PMC_22374972","title":"Fasting energy homeostasis in mice with adipose deficiency of desnutrin/adipose triglyceride lipase.","date":"2012","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/22374972","citation_count":86,"is_preprint":false},{"pmid":"21544567","id":"PMC_21544567","title":"The phenotypic spectrum of neutral lipid storage myopathy due to mutations in the PNPLA2 gene.","date":"2011","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21544567","citation_count":82,"is_preprint":false},{"pmid":"22039468","id":"PMC_22039468","title":"The minimal domain of adipose triglyceride lipase (ATGL) ranges until leucine 254 and can be activated and inhibited by CGI-58 and G0S2, respectively.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22039468","citation_count":77,"is_preprint":false},{"pmid":"23408028","id":"PMC_23408028","title":"Skeletal muscle PLIN proteins, ATGL and CGI-58, interactions at rest and following stimulated contraction.","date":"2013","source":"American journal of physiology. Regulatory, integrative and comparative physiology","url":"https://pubmed.ncbi.nlm.nih.gov/23408028","citation_count":76,"is_preprint":false},{"pmid":"16644682","id":"PMC_16644682","title":"The ATGL gene is associated with free fatty acids, triglycerides, and type 2 diabetes.","date":"2006","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/16644682","citation_count":76,"is_preprint":false},{"pmid":"16752181","id":"PMC_16752181","title":"Human adipose triglyceride lipase (PNPLA2) is not regulated by obesity and exhibits low in vitro triglyceride hydrolase activity.","date":"2006","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/16752181","citation_count":76,"is_preprint":false},{"pmid":"29472527","id":"PMC_29472527","title":"Hints on ATGL implications in cancer: beyond bioenergetic clues.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29472527","citation_count":71,"is_preprint":false},{"pmid":"25202121","id":"PMC_25202121","title":"Lipid droplet protein LID-1 mediates ATGL-1-dependent lipolysis during fasting in Caenorhabditis elegans.","date":"2014","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25202121","citation_count":70,"is_preprint":false},{"pmid":"22687626","id":"PMC_22687626","title":"Fenofibrate lowers lipid accumulation in myotubes by modulating the PPARα/AMPK/FoxO1/ATGL pathway.","date":"2012","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22687626","citation_count":63,"is_preprint":false},{"pmid":"32729974","id":"PMC_32729974","title":"The novel non-steroidal MR antagonist finerenone improves metabolic parameters in high-fat diet-fed mice and activates brown adipose tissue via AMPK-ATGL pathway.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/32729974","citation_count":60,"is_preprint":false},{"pmid":"27559856","id":"PMC_27559856","title":"ABHD5 interacts with BECN1 to regulate autophagy and tumorigenesis of colon cancer independent of PNPLA2.","date":"2016","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/27559856","citation_count":58,"is_preprint":false},{"pmid":"29986925","id":"PMC_29986925","title":"Coordination Among Lipid Droplets, Peroxisomes, and Mitochondria Regulates Energy Expenditure Through the CIDE-ATGL-PPARα Pathway in Adipocytes.","date":"2018","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/29986925","citation_count":57,"is_preprint":false},{"pmid":"18224330","id":"PMC_18224330","title":"Adipose triglyceride lipase (ATGL) expression in human skeletal muscle is type I (oxidative) fiber specific.","date":"2008","source":"Histochemistry and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18224330","citation_count":56,"is_preprint":false},{"pmid":"21789191","id":"PMC_21789191","title":"Interaction between the triglyceride lipase ATGL and the Arf1 activator GBF1.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21789191","citation_count":54,"is_preprint":false},{"pmid":"24836204","id":"PMC_24836204","title":"A novel mutation in PNPLA2 causes neutral lipid storage disease with myopathy and triglyceride deposit cardiomyovasculopathy: a case report and literature review.","date":"2014","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/24836204","citation_count":52,"is_preprint":false},{"pmid":"30367149","id":"PMC_30367149","title":"Forcing ATGL expression in hepatocarcinoma cells imposes glycolytic rewiring through PPAR-α/p300-mediated acetylation of p53.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30367149","citation_count":48,"is_preprint":false},{"pmid":"22990388","id":"PMC_22990388","title":"Contribution of novel ATGL missense mutations to the clinical phenotype of NLSD-M: a strikingly low amount of lipase activity may preserve cardiac function.","date":"2012","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22990388","citation_count":47,"is_preprint":false},{"pmid":"39550037","id":"PMC_39550037","title":"PNPLA3(148M) is a gain-of-function mutation that promotes hepatic steatosis by inhibiting ATGL-mediated triglyceride hydrolysis.","date":"2024","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/39550037","citation_count":46,"is_preprint":false},{"pmid":"18189154","id":"PMC_18189154","title":"Developmental, hormonal, and nutritional regulation of porcine adipose triglyceride lipase (ATGL).","date":"2008","source":"Lipids","url":"https://pubmed.ncbi.nlm.nih.gov/18189154","citation_count":46,"is_preprint":false},{"pmid":"27677764","id":"PMC_27677764","title":"A beta cell ATGL-lipolysis/adipose tissue axis controls energy homeostasis and body weight via insulin secretion in mice.","date":"2016","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/27677764","citation_count":45,"is_preprint":false},{"pmid":"25852007","id":"PMC_25852007","title":"ATGL-mediated triglyceride turnover and the regulation of mitochondrial capacity in skeletal muscle.","date":"2015","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25852007","citation_count":42,"is_preprint":false},{"pmid":"23204327","id":"PMC_23204327","title":"Distinct mechanisms regulate ATGL-mediated adipocyte lipolysis by lipid droplet coat proteins.","date":"2012","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/23204327","citation_count":42,"is_preprint":false},{"pmid":"20336671","id":"PMC_20336671","title":"17beta-estradiol supplementation attenuates ovariectomy-induced increases in ATGL signaling and reduced perilipin expression in visceral adipose tissue.","date":"2010","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20336671","citation_count":41,"is_preprint":false},{"pmid":"18657972","id":"PMC_18657972","title":"Distal lipid storage myopathy due to PNPLA2 mutation.","date":"2008","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/18657972","citation_count":41,"is_preprint":false},{"pmid":"19695247","id":"PMC_19695247","title":"Chronic TNFalpha and cAMP pre-treatment of human adipocytes alter HSL, ATGL and perilipin to regulate basal and stimulated lipolysis.","date":"2009","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/19695247","citation_count":40,"is_preprint":false},{"pmid":"25956450","id":"PMC_25956450","title":"Novel missense mutations in PNPLA2 causing late onset and clinical heterogeneity of neutral lipid storage disease with myopathy in three siblings.","date":"2015","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25956450","citation_count":40,"is_preprint":false},{"pmid":"24610891","id":"PMC_24610891","title":"Hepatic ATGL mediates PPAR-α signaling and fatty acid channeling through an L-FABP independent mechanism.","date":"2014","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/24610891","citation_count":39,"is_preprint":false},{"pmid":"27179362","id":"PMC_27179362","title":"ATGL and DGAT1 are involved in the turnover of newly synthesized triacylglycerols in hepatic stellate cells.","date":"2016","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/27179362","citation_count":38,"is_preprint":false},{"pmid":"32542055","id":"PMC_32542055","title":"The ATGL lipase cooperates with ABHD5 to mobilize lipids for hepatitis C virus assembly.","date":"2020","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/32542055","citation_count":38,"is_preprint":false},{"pmid":"28459858","id":"PMC_28459858","title":"Epistatic interaction between the lipase-encoding genes Pnpla2 and Lipe causes liposarcoma in mice.","date":"2017","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28459858","citation_count":37,"is_preprint":false},{"pmid":"26330055","id":"PMC_26330055","title":"ATGL and CGI-58 are lipid droplet proteins of the hepatic stellate cell line HSC-T6.","date":"2015","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/26330055","citation_count":36,"is_preprint":false},{"pmid":"28194887","id":"PMC_28194887","title":"Atgl deficiency induces podocyte apoptosis and leads to glomerular filtration barrier damage.","date":"2017","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/28194887","citation_count":36,"is_preprint":false},{"pmid":"19626423","id":"PMC_19626423","title":"Regulation of ATGL expression mediated by leptin in vitro in porcine adipocyte lipolysis.","date":"2009","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19626423","citation_count":34,"is_preprint":false},{"pmid":"28726642","id":"PMC_28726642","title":"Coordinated transcriptional control of adipocyte triglyceride lipase (Atgl) by transcription factors Sp1 and peroxisome proliferator-activated receptor γ (PPARγ) during adipocyte differentiation.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28726642","citation_count":34,"is_preprint":false},{"pmid":"27485820","id":"PMC_27485820","title":"PPARα-ATGL pathway improves muscle mitochondrial metabolism: implication in aging.","date":"2016","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/27485820","citation_count":33,"is_preprint":false},{"pmid":"25890298","id":"PMC_25890298","title":"PEDF and PEDF-derived peptide 44mer stimulate cardiac triglyceride degradation via ATGL.","date":"2015","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25890298","citation_count":33,"is_preprint":false},{"pmid":"31185001","id":"PMC_31185001","title":"Targeting ATGL to rescue BSCL2 lipodystrophy and its associated cardiomyopathy.","date":"2019","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/31185001","citation_count":32,"is_preprint":false},{"pmid":"22951290","id":"PMC_22951290","title":"Fat-reducing effects of dehydroepiandrosterone involve upregulation of ATGL and HSL expression, and stimulation of lipolysis in adipose tissue.","date":"2012","source":"Steroids","url":"https://pubmed.ncbi.nlm.nih.gov/22951290","citation_count":31,"is_preprint":false},{"pmid":"31311719","id":"PMC_31311719","title":"ATGL-1 mediates the effect of dietary restriction and the insulin/IGF-1 signaling pathway on longevity in C. elegans.","date":"2019","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/31311719","citation_count":30,"is_preprint":false},{"pmid":"23145367","id":"PMC_23145367","title":"Distinct roles for alpha-beta hydrolase domain 5 (ABHD5/CGI-58) and adipose triglyceride lipase (ATGL/PNPLA2) in lipid metabolism and signaling.","date":"2012","source":"Adipocyte","url":"https://pubmed.ncbi.nlm.nih.gov/23145367","citation_count":29,"is_preprint":false},{"pmid":"31412256","id":"PMC_31412256","title":"ATGL/CGI-58-Dependent Hydrolysis of a Lipid Storage Pool in Murine Enterocytes.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31412256","citation_count":29,"is_preprint":false},{"pmid":"39357546","id":"PMC_39357546","title":"Inhibition of ATGL alleviates MASH via impaired PPARα signalling that favours hydrophilic bile acid composition in mice.","date":"2024","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/39357546","citation_count":28,"is_preprint":false},{"pmid":"39143266","id":"PMC_39143266","title":"S-acylation of ATGL is required for lipid droplet homoeostasis in hepatocytes.","date":"2024","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/39143266","citation_count":28,"is_preprint":false},{"pmid":"38561547","id":"PMC_38561547","title":"Glucose controls lipolysis through Golgi PtdIns4P-mediated regulation of ATGL.","date":"2024","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/38561547","citation_count":28,"is_preprint":false},{"pmid":"25381252","id":"PMC_25381252","title":"The hepatitis C virus core protein inhibits adipose triglyceride lipase (ATGL)-mediated lipid mobilization and enhances the ATGL interaction with comparative gene identification 58 (CGI-58) and lipid droplets.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25381252","citation_count":28,"is_preprint":false},{"pmid":"34845203","id":"PMC_34845203","title":"Elevated ATGL in colon cancer cells and cancer stem cells promotes metabolic and tumorigenic reprogramming reinforced by obesity.","date":"2021","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/34845203","citation_count":28,"is_preprint":false},{"pmid":"25287355","id":"PMC_25287355","title":"A myopathy with unusual features caused by PNPLA2 gene mutations.","date":"2015","source":"Muscle & nerve","url":"https://pubmed.ncbi.nlm.nih.gov/25287355","citation_count":26,"is_preprint":false},{"pmid":"22815850","id":"PMC_22815850","title":"Higher levels of ATGL are associated with exercise-induced enhancement of lipolysis in rat epididymal adipocytes.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22815850","citation_count":26,"is_preprint":false},{"pmid":"39748508","id":"PMC_39748508","title":"ATGL regulates renal fibrosis by reprogramming lipid metabolism during the transition from AKI to CKD.","date":"2025","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/39748508","citation_count":25,"is_preprint":false},{"pmid":"39326768","id":"PMC_39326768","title":"Blockage of ATGL-mediated breakdown of lipid droplets in microglia alleviates neuroinflammatory and behavioural responses to lipopolysaccharides.","date":"2024","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/39326768","citation_count":25,"is_preprint":false},{"pmid":"31035700","id":"PMC_31035700","title":"An Epistatic Interaction between Pnpla2 and Lipe Reveals New Pathways of Adipose Tissue Lipolysis.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31035700","citation_count":25,"is_preprint":false},{"pmid":"25814662","id":"PMC_25814662","title":"4E-BPs Control Fat Storage by Regulating the Expression of Egr1 and ATGL.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25814662","citation_count":25,"is_preprint":false},{"pmid":"36746922","id":"PMC_36746922","title":"Restoration of lipid homeostasis between TG and PE by the LXRα-ATGL/EPT1 axis ameliorates hepatosteatosis.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36746922","citation_count":25,"is_preprint":false},{"pmid":"21073837","id":"PMC_21073837","title":"A novel PNPLA2 mutation causes neutral lipid storage disease with myopathy (NLSDM) presenting muscular dystrophic features with lipid storage and rimmed vacuoles.","date":"2010","source":"Clinical neuropathology","url":"https://pubmed.ncbi.nlm.nih.gov/21073837","citation_count":25,"is_preprint":false},{"pmid":"33824421","id":"PMC_33824421","title":"Loss of ephrin B2 receptor (EPHB2) sets lipid rheostat by regulating proteins DGAT1 and ATGL inducing lipid droplet storage in prostate cancer cells.","date":"2021","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33824421","citation_count":25,"is_preprint":false},{"pmid":"35912266","id":"PMC_35912266","title":"Recent Advances on the Role of ATGL in Cancer.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35912266","citation_count":24,"is_preprint":false},{"pmid":"32454271","id":"PMC_32454271","title":"Effect of salt promote the muscle triglyceride hydrolysis during dry-salting by inducing the phosphorylation of adipose tissue triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL) and lipid droplets splitting.","date":"2020","source":"Food chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32454271","citation_count":24,"is_preprint":false},{"pmid":"28179319","id":"PMC_28179319","title":"Adipose Triglyceride Lipase (ATGL) Expression Is Associated with Adiposity and Tumor Stromal Proliferation in Patients with Pancreatic Ductal Adenocarcinoma.","date":"2017","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28179319","citation_count":24,"is_preprint":false},{"pmid":"35372814","id":"PMC_35372814","title":"The vesicular transporter STX11 governs ATGL-mediated hepatic lipolysis and lipophagy.","date":"2022","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/35372814","citation_count":23,"is_preprint":false},{"pmid":"28578400","id":"PMC_28578400","title":"Lipid Droplet-Associated Hydrolase Promotes Lipid Droplet Fusion and Enhances ATGL Degradation and Triglyceride Accumulation.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28578400","citation_count":23,"is_preprint":false},{"pmid":"34416900","id":"PMC_34416900","title":"Long non-coding RNA NEAT1 facilitates the growth, migration, and invasion of ovarian cancer cells via the let-7 g/MEST/ATGL axis.","date":"2021","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/34416900","citation_count":23,"is_preprint":false},{"pmid":"20621463","id":"PMC_20621463","title":"ATGL and HSL are not coordinately regulated in response to fuel partitioning in fasted rats.","date":"2011","source":"The Journal of nutritional biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20621463","citation_count":22,"is_preprint":false},{"pmid":"33449950","id":"PMC_33449950","title":"Palmitate induces fat accumulation via repressing FoxO1-mediated ATGL-dependent lipolysis in HepG2 hepatocytes.","date":"2021","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/33449950","citation_count":22,"is_preprint":false},{"pmid":"23232698","id":"PMC_23232698","title":"Symptomatic lipid storage in carriers for the PNPLA2 gene.","date":"2012","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/23232698","citation_count":21,"is_preprint":false},{"pmid":"22832386","id":"PMC_22832386","title":"Novel PNPLA2 gene mutations in Chinese Han patients causing neutral lipid storage disease with myopathy.","date":"2012","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22832386","citation_count":21,"is_preprint":false},{"pmid":"33450726","id":"PMC_33450726","title":"Localized increases in CEPT1 and ATGL elevate plasmalogen phosphatidylcholines in HDLs contributing to atheroprotective lipid profiles in hyperglycemic GCK-MODY.","date":"2021","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/33450726","citation_count":20,"is_preprint":false},{"pmid":"36604676","id":"PMC_36604676","title":"BETi enhance ATGL expression and its lipase activity to exert their antitumoral effects in triple-negative breast cancer (TNBC) cells.","date":"2023","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/36604676","citation_count":19,"is_preprint":false},{"pmid":"28400046","id":"PMC_28400046","title":"Atgl gene deletion predisposes to proximal tubule damage by impairing the fatty acid metabolism.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28400046","citation_count":19,"is_preprint":false},{"pmid":"24074500","id":"PMC_24074500","title":"PNPLA2 mutation: a paediatric case with early onset but indolent course.","date":"2013","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/24074500","citation_count":19,"is_preprint":false},{"pmid":"33508319","id":"PMC_33508319","title":"ATGL activity regulates GLUT1-mediated glucose uptake and lactate production via TXNIP stability in adipocytes.","date":"2021","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33508319","citation_count":19,"is_preprint":false},{"pmid":"30926171","id":"PMC_30926171","title":"PEDF promotes nuclear degradation of ATGL through COP1.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30926171","citation_count":18,"is_preprint":false},{"pmid":"22964912","id":"PMC_22964912","title":"A novel mutation in PNPLA2 leading to neutral lipid storage disease with myopathy.","date":"2012","source":"Archives of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/22964912","citation_count":18,"is_preprint":false},{"pmid":"21958877","id":"PMC_21958877","title":"Metformin regulates hepatic lipid metabolism through activating AMP-activated protein kinase and inducing ATGL in laying hens.","date":"2011","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21958877","citation_count":18,"is_preprint":false},{"pmid":"27248498","id":"PMC_27248498","title":"Regulation of G0/G1 Switch Gene 2 (G0S2) Protein Ubiquitination and Stability by Triglyceride Accumulation and ATGL Interaction.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27248498","citation_count":18,"is_preprint":false},{"pmid":"33675111","id":"PMC_33675111","title":"Resting skeletal muscle PNPLA2 (ATGL) and CPT1B are associated with peak fat oxidation rates in men and women but do not explain observed sex differences.","date":"2021","source":"Experimental physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33675111","citation_count":17,"is_preprint":false},{"pmid":"32777979","id":"PMC_32777979","title":"Burkholderia pseudomallei interferes with host lipid metabolism via NR1D2-mediated PNPLA2/ATGL suppression to block autophagy-dependent inhibition of infection.","date":"2020","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/32777979","citation_count":17,"is_preprint":false},{"pmid":"18679582","id":"PMC_18679582","title":"cDNA cloning, characterization, and variation analysis of chicken adipose triglyceride lipase (ATGL) gene.","date":"2008","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18679582","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52401,"output_tokens":8918,"usd":0.145486,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19135,"output_tokens":5413,"usd":0.1155,"stage2_stop_reason":"end_turn"},"total_usd":0.260986,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"Desnutrin/PNPLA2 encodes a 486-amino acid protein containing a patatin-like domain; ectopic overexpression in transfected cells increases triglyceride hydrolysis, establishing its lipase function. The fusion protein localizes to the cytoplasm as shown by confocal microscopy of EGFP-tagged desnutrin.\",\n      \"method\": \"Transfection/overexpression, triglyceride hydrolysis assay, confocal microscopy of EGFP-tagged protein\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct in vitro hydrolysis assay plus localization experiment; founding characterization paper with functional readout\",\n      \"pmids\": [\"15337759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Loss-of-function mutations in PNPLA2 (truncations affecting the hydrophobic domain but sparing the patatin active site) cause neutral lipid storage disease with myopathy (NLSDM), with triglyceride accumulation mimicked by siRNA knockdown of ATGL, establishing PNPLA2 as the rate-limiting triglyceride hydrolase in multiple tissues.\",\n      \"method\": \"Patient mutation analysis, siRNA knockdown with lipid accumulation readout\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human genetics combined with siRNA loss-of-function reproducing the biochemical phenotype; replicated by multiple subsequent mutation reports\",\n      \"pmids\": [\"17187067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ATGL-catalyzed lipolysis of cellular triglycerides generates lipid ligands required for PPAR-α and PPAR-δ activation; in the heart, ATGL deficiency decreases PGC-1α/β expression, disrupts mitochondrial substrate oxidation and respiration, causing cardiomyopathy that is fully reversed by pharmacological PPAR-α agonist treatment.\",\n      \"method\": \"Atgl-knockout mouse model, mitochondrial respiration assays, PPAR-α agonist rescue, gene expression analysis\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genetic KO with defined mechanistic readouts and pharmacological rescue; replicated in multiple tissues and labs\",\n      \"pmids\": [\"21857651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"AMPK phosphorylates desnutrin/ATGL at serine 406, increasing its triacylglycerol hydrolase activity. Adipose-specific ATGL ablation converts brown adipose tissue to a WAT-like tissue with impaired thermogenesis and reduced UCP-1/PPARα signaling.\",\n      \"method\": \"Phosphorylation site mutagenesis, kinase assay, adipose-specific knockout mouse, thermogenesis assay, gene expression\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — site-specific phosphorylation established by mutagenesis and kinase assay; confirmed in vivo with tissue-specific KO\",\n      \"pmids\": [\"21641555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The minimal catalytically active domain of ATGL extends to leucine 254 (beyond the canonical patatin domain, Ile10–Leu178). This minimal fragment retains triacylglycerol hydrolase activity and can be co-activated by CGI-58 and inhibited by G0S2, and is sufficient for protein–protein interactions with both regulators. A 3D homology model of the minimal domain was generated.\",\n      \"method\": \"Domain truncation/mutagenesis, in vitro lipase activity assay, protein–protein interaction, homology modeling\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution of activity with truncation mutants plus direct binding assays; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"22039468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"UBXD8 directly binds ATGL on lipid droplets and promotes dissociation of the ATGL co-activator CGI-58, thereby inhibiting ATGL-mediated triacylglycerol hydrolysis and increasing lipid droplet size. UBXD8 recruits p97/VCP to lipid droplets through this interaction.\",\n      \"method\": \"Co-immunoprecipitation, direct binding assay, LD size measurement, overexpression/knockdown of UBXD8\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct protein binding established, functional consequence on LD lipolysis demonstrated, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"23297223\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"G0S2 inhibits ATGL activity and ATGL-mediated lipid droplet degradation. G0S2 binds ATGL independently of its activity state or the presence of CGI-58. CGI-58 co-activation cannot overcome G0S2-mediated inhibition, indicating non-competing regulatory mechanisms.\",\n      \"method\": \"Co-immunoprecipitation, lipid droplet morphology assay, overexpression studies\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP and functional LD assay in single lab; mechanistic details of non-competition established\",\n      \"pmids\": [\"20676045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The C-terminal hydrophobic domain of ATGL is required for lipid droplet targeting and CGI-58-independent LD degradation. A deletion mutant lacking this domain fails to localize to LDs and cannot affect their morphology, though CGI-58 co-expression partially rescues this.\",\n      \"method\": \"Domain deletion mutagenesis, fluorescence localization, lipid droplet morphology assay\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis with localization and functional readout; single lab\",\n      \"pmids\": [\"20676045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"FoxO1 directly binds to two FoxO1-binding sites in the ATGL promoter and transcriptionally activates ATGL expression. Insulin controls nucleo-cytoplasmic shuttling of FoxO1 and regulates its interaction with the endogenous ATGL promoter in adipocytes. FoxO1 knockdown decreases ATGL expression and attenuates lipolysis.\",\n      \"method\": \"Luciferase reporter assay, ChIP, siRNA knockdown, lipolysis assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ChIP + reporter assay + knockdown with functional readout; multiple orthogonal methods in single lab\",\n      \"pmids\": [\"19297333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Insulin downregulates ATGL mRNA via PI3-kinase and p70 S6 kinase pathways. TNF-α downregulates ATGL in parallel with PPARγ reduction, effects attenuated by MEK, PI3K, and mTOR inhibitors. PPARγ transcriptionally activates the ATGL promoter (identified through 5'-flanking region luciferase reporter deletion analysis).\",\n      \"method\": \"Luciferase reporter assay with promoter deletions, pharmacological inhibitors, adipocyte cell culture\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay with deletion series plus pharmacological dissection; single lab\",\n      \"pmids\": [\"16705060\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Insulin inhibits ATGL transcription through an evolutionarily conserved mTORC1–Egr1 pathway. Egr1 directly inhibits the ATGL promoter in vitro and in cultured adipocytes. The pathway was identified by genetic screen in yeast (Msn4p/Tor1 axis as ATGL ortholog regulator) and validated in mammalian cells.\",\n      \"method\": \"Yeast genetic screen, Egr1 promoter binding assay, adipocyte knockdown/overexpression, high-fat-diet mouse model\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genetic epistasis screen + direct promoter binding + in vivo validation; multiple orthogonal methods across organisms\",\n      \"pmids\": [\"23858058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SIRT1 controls ATGL transcription by deacetylating FoxO1, thereby regulating FoxO1's functional activity at the ATGL promoter. SIRT1 knockdown decreases ATGL expression and attenuates lipolysis in adipocytes.\",\n      \"method\": \"shRNA knockdown, lipolysis assay, dominant-negative AMPK cell line, gene expression analysis\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — shRNA knockdown with functional and transcriptional readouts; single lab, mechanistic link to FoxO1 acetylation established\",\n      \"pmids\": [\"21743036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ATGL-catalyzed lipolysis positively regulates SIRT1 deacetylase activity to promote PGC-1α signaling and oxidative metabolism, independent of changes in NAD+. ATGL mediates β-adrenergic signaling effects on SIRT1 activity and PPAR-α target gene expression, establishing SIRT1 as a critical node linking lipolysis to transcriptional regulation of oxidative metabolism.\",\n      \"method\": \"ATGL overexpression/knockdown, SIRT1 deacetylase activity assay, gene expression, β-adrenergic stimulation\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — enzymatic activity assay plus genetic manipulation; single lab\",\n      \"pmids\": [\"25614670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Desnutrin/ATGL ablation in pancreatic β-cells impairs glucose-stimulated insulin secretion (GSIS) by reducing lipolysis-derived PPARδ ligands, which are required for normal mitochondrial oxidative gene expression and ATP production. Synthetic PPARδ (but not PPARα) agonist restores GSIS in β-cell-specific KO mice.\",\n      \"method\": \"β-cell-specific Atgl KO, GSIS assay, mitochondrial respiration, PPARδ agonist rescue, adenoviral ATGL re-expression\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — tissue-specific KO, rescue with specific agonist, adenoviral reconstitution confirming specificity; multiple orthogonal methods\",\n      \"pmids\": [\"24268737\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FSP27 (amino acids 120–220) directly interacts with ATGL to inhibit its lipolytic function and promote triglyceride storage in human adipocytes. FSP27 depletion increases lipolysis and inhibits insulin signaling via reduced AKT phosphorylation, which is rescued by ATGL depletion or exogenous FSP27 expression.\",\n      \"method\": \"Co-immunoprecipitation, domain mapping, siRNA knockdown, lipolysis assay, insulin signaling assay in human adipocytes\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding domain mapped, functional consequences in human cells with multiple orthogonal methods\",\n      \"pmids\": [\"24627478\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"GBF1 (Golgi Brefeldin A resistance factor 1) and ATGL interact directly; multiple contact sites exist: the C-terminal region of ATGL interacts with N-terminal (including Sec7) domains of GBF1, while the patatin (lipase) domain of ATGL interacts with GBF1 HDS1 and HDS2 C-terminal domains. This interaction contributes to ATGL delivery to lipid droplets via a GBF1/Arf1/COPI trafficking pathway.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, direct protein binding, subcellular localization of GBF1 domain fragments\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid + Co-IP + direct binding; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"21789191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Perilipin 1, but not FSP27, directly inhibits ATGL triacylglycerol hydrolase activity in vitro and attenuates CGI-58-dependent co-activation of ATGL. Perilipin 1 is required for isoproterenol-stimulated translocation of ATGL to lipid droplets, while FSP27 constitutively limits LD presence of ATGL.\",\n      \"method\": \"In vitro triacylglycerol hydrolase assay, siRNA knockdown, overexpression, LD translocation imaging\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro enzymatic assay with direct inhibition demonstrated plus cell-based localization studies; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"23204327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In skeletal muscle, contraction stimulation increases the ATGL–CGI-58 interaction by 128%. ATGL interacts with PLIN2, PLIN3, and PLIN5 at rest; the PLIN2–ATGL interaction decreases 21% with contraction. PLIN2 does not interact with CGI-58, suggesting PLINs differentially regulate ATGL–CGI-58 association.\",\n      \"method\": \"Co-immunoprecipitation from rat skeletal muscle at rest vs. electrically stimulated contraction\",\n      \"journal\": \"American journal of physiology. Regulatory, integrative and comparative physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP in physiologically relevant context replicated for multiple interaction partners; single lab\",\n      \"pmids\": [\"23408028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In vivo, adipose-specific knockout of both AMPK α1 and α2 subunits abolishes phosphorylation of desnutrin/ATGL at S406, reducing triacylglycerol hydrolase activity and lowering basal lipolysis, providing direct in vivo evidence that AMPK phosphorylates and activates ATGL. AMPK-ASKO mice also show defective HSL phosphorylation at S565.\",\n      \"method\": \"Adipose-specific AMPK double-knockout mouse, phosphorylation analysis, TAG hydrolase activity assay, adipocyte lipolysis assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic KO confirming kinase–substrate relationship; replicates and extends prior in vitro phosphorylation finding\",\n      \"pmids\": [\"27185873\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ATGL catalyzes FAHFA (fatty acid esters of hydroxy fatty acids) biosynthesis via a transacylation reaction, esterifying a hydroxy fatty acid with a fatty acid from triglyceride or diglyceride. Catalytically dead ATGL fails to increase FAHFA production; chemical inhibition or genetic deletion of Atgl reduces FAHFA and FAHFA-TG levels by 80–90% in adipose tissue. ATGL transacylase activity is present in human adipose tissue.\",\n      \"method\": \"Recombinant ATGL in vitro transacylation assay, catalytic dead mutant, chemical inhibition (atglistatin), adipose-specific Atgl KO mouse, chemical biology/proteomics\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with recombinant protein + mutagenesis + genetic KO + pharmacological inhibition; replicated in human tissue\",\n      \"pmids\": [\"35676490\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"zDHHC11 S-acylates ATGL at cysteine 15, and this modification is required for ATGL catalytic activity. Preventing S-acylation (C15 mutation) renders ATGL catalytically inactive despite proper lipid droplet localization, causing LD accumulation and defective lipolysis/lipophagy. Overexpression of zDHHC11 reduces LD size; its elimination enlarges LDs.\",\n      \"method\": \"Site-directed mutagenesis (C15), S-acylation assay, lipolysis assay, LD imaging, overexpression/knockdown in hepatocytes and mice\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis of acylation site with enzymatic activity readout and in vivo validation; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"39143266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PNPLA3(148M) promotes hepatic steatosis as a gain-of-function by accumulating on lipid droplets and sequestering ABHD5 (CGI-58) away from ATGL, thereby limiting ATGL-mediated TG hydrolysis. ABHD5 activates both PNPLA3 and ATGL in vitro. PNPLA3(148M)-associated inhibition of TG hydrolysis requires ATGL expression and LD localization of PNPLA3. Overexpression of ABHD5 reversed hepatic steatosis in Pnpla3M/M mice.\",\n      \"method\": \"NanoBiT complementation assay, in vitro TG hydrolysis with purified recombinant proteins, liver-specific Atgl-KO mice, adenoviral/AAV expression, immunocytochemistry\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro reconstitution with purified proteins + NanoBiT interaction assay + genetic mouse models; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"39550037\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Intracellular glucose depletion lowers Golgi PtdIns4P levels, reducing assembly of the CUL7FBXW8 E3 ubiquitin ligase complex in the Golgi, which decreases polyubiquitylation of ATGL and enhances ATGL-driven lipolysis. This constitutes a cell-intrinsic glucose-sensing mechanism controlling FA liberation from lipid droplets.\",\n      \"method\": \"PtdIns4P manipulation, CUL7FBXW8 assembly assay, ATGL ubiquitylation assay, genetic/pharmacological manipulation in mouse models and ex vivo human liver perfusion\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — biochemical ubiquitylation assay + genetic manipulation in vivo + human tissue validation; single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"38561547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PEDF promotes proteasomal degradation of ATGL via COP1-mediated polyubiquitylation. PEDF enhances nuclear import of ATGL for its subsequent proteasomal degradation in the nucleus. This COP1–ATGL axis controls hepatocyte lipid accumulation and mobilization.\",\n      \"method\": \"Co-immunoprecipitation, proteasome inhibitor assay, nuclear fractionation, overexpression/knockdown of COP1 and PEDF in hepatocytes\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP + fractionation + functional lipid assay; single lab, mechanistic pathway defined\",\n      \"pmids\": [\"30926171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"LDAH (lipid droplet-associated hydrolase) enhances polyubiquitination and proteasomal degradation of ATGL, thereby increasing TAG levels and LD size. Co-expression of ATGL reverses the LD phenotype induced by LDAH overexpression.\",\n      \"method\": \"Ubiquitination assay, pulse-chase, overexpression/knockdown in HEK293 cells, TAG measurement, LD morphology\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — ubiquitination assay and functional rescue; single lab\",\n      \"pmids\": [\"28578400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"G0S2 protein stability is regulated by K48-linked polyubiquitination at lysine 25; mutation of K25 abolishes ubiquitination and stabilizes G0S2. ATGL expression stabilizes G0S2 protein (but not mRNA); G0S2 protein levels are reduced in adipose tissue of ATGL-deficient mice, confirming ATGL's role in G0S2 stabilization.\",\n      \"method\": \"Ubiquitination assay, site-directed mutagenesis (K25), Atgl-KO mouse tissue analysis, protein stability assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — mutagenesis of ubiquitination site plus in vivo KO confirmation; single lab\",\n      \"pmids\": [\"27248498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ATGL protein is expressed in human skeletal muscle exclusively in type I (oxidative) muscle fibers, as established by immunohistochemistry and immunofluorescence with fiber-type markers.\",\n      \"method\": \"Immunohistochemistry, immunofluorescence, fiber-type co-staining in human vastus lateralis biopsies\",\n      \"journal\": \"Histochemistry and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct localization experiment in human tissue; single lab, single method but clear result\",\n      \"pmids\": [\"18224330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Hepatic ATGL channels hydrolyzed fatty acids preferentially to β-oxidation and induces PPAR-α signaling independent of liver fatty acid binding protein (L-FABP). L-FABP deletion does not impair ATGL-mediated FA channeling to mitochondria or PPAR-α target gene regulation.\",\n      \"method\": \"Adenovirus-mediated ATGL knockdown/overexpression in WT and L-FABP KO mice, primary hepatocyte oxidation assays, serum β-hydroxybutyrate measurement\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis (double KO) with functional metabolic readout; single lab\",\n      \"pmids\": [\"24610891\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ATGL cooperates with ABHD5/CGI-58 to mobilize lipids from lipid droplets for hepatitis C virus assembly and lipoprotein morphogenesis. ABHD5 residues critical for ATGL activation, when grafted onto the non-activating paralog ABHD4, restored both pro-viral and lipolytic functions, defining the ABHD5–ATGL protein interface required for co-lipase activity.\",\n      \"method\": \"ATGL expression modulation, chemical inhibition (atglistatin), ABHD5 chimeric protein engineering, co-immunoprecipitation, lipid droplet lipolysis assay, viral production assay\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — chimeric protein rescue experiment defining interaction interface + multiple orthogonal methods; single lab\",\n      \"pmids\": [\"32542055\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"STX11 directly binds ATGL via its C-terminal domain interacting with the patatin domain-containing segment of ATGL, preventing ATGL translocation to lipid droplets by recruiting ATGL to the ER. STX11 deficiency in hepatocytes promotes lipolysis via ATGL-SIRT1 signaling and enhances lipophagy.\",\n      \"method\": \"Co-immunoprecipitation, domain mapping, subcellular localization imaging, overexpression/knockdown, lipid hydrolysis assay\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — direct binding with domain mapping and functional localization consequence; single lab\",\n      \"pmids\": [\"35372814\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In the intestine, ATGL/CGI-58 specifically catalyzes hydrolysis of a lipid storage pool derived from basolateral (blood-side) lipid uptake/secretion–re-uptake cycle, but is not involved in providing substrates for chylomicron synthesis from dietary lipids.\",\n      \"method\": \"Intestine-specific ATGL/CGI-58 double KO mice, dietary lipid challenge, lipid droplet accumulation analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — tissue-specific double KO with defined phenotypic dissection of two lipid pools; single lab\",\n      \"pmids\": [\"31412256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"HCV core protein localizes to lipid droplet surfaces and inhibits ATGL-mediated lipolysis without directly interacting with ATGL or CGI-58, but unexpectedly increases ATGL–CGI-58 interaction and recruitment of both to LDs. ATGL-KO MEFs expressing core show no decrease in TG degradation, confirming core acts through ATGL.\",\n      \"method\": \"Co-immunoprecipitation, ATGL-KO mouse embryonic fibroblasts, ex vivo LD TG hydrolysis assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO epistasis plus Co-IP and biochemical assay; single lab\",\n      \"pmids\": [\"25381252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Combined adipose-specific deficiency of ATGL and HSL (DAKO mice) causes fully penetrant liposarcoma in all mice by 11–14 months, establishing a genetic epistatic interaction between Pnpla2 and Lipe; this phenotype does not occur with either single knockout alone.\",\n      \"method\": \"Double adipose-specific KO mouse (epistasis), tumor histology, transcriptome analysis\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — fully penetrant genetic epistasis established in vivo with clear phenotype; double vs. single KO controls\",\n      \"pmids\": [\"28459858\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"When HSL is deficient, ATGL functions as a transacylase, transferring an acyl group from one diacylglycerol to another, forming a triglyceride plus a monoglyceride. This ATGL transacylase activity was abolished by a specific ATGL inhibitor, revealing a previously unknown physiological redundancy between ATGL and HSL.\",\n      \"method\": \"Radiolabeled DG incubation with HSL-deficient lipid droplet fractions, ATGL-specific inhibitor (atglistatin) treatment\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — biochemical transacylase assay with specific inhibitor control; single lab\",\n      \"pmids\": [\"31035700\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ATGL overexpression in ATGL-deficient hepatocellular carcinoma cells activates PPAR-α/p300-mediated acetylation and accumulation of p53 protein (without altering p53 mRNA), rewiring metabolism toward oxidative fatty acid metabolism and reducing glucose uptake/glycolysis.\",\n      \"method\": \"ATGL overexpression in HCC cell lines, p53 knockdown/KO epistasis, PPAR-α/p300 inhibition, metabolic assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis experiments with p53 KO; multiple pathway readouts; single lab\",\n      \"pmids\": [\"30367149\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ATGL-mediated lipolysis regulates glucose uptake in adipocytes via TXNIP stability: cAMP-induced ATGL activation promotes TXNIP degradation, selectively inducing GLUT1 surface localization and glucose uptake. ATGL knockdown prevents cAMP-dependent TXNIP degradation and reduces glucose uptake; this mechanism was validated in human primary adipocytes.\",\n      \"method\": \"siRNA knockdown, ATGL overexpression, TXNIP stability assay, GLUT1 surface localization, glucose uptake assay in 3T3-L1 and human primary adipocytes\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway defined with knockdown and overexpression, validated in human cells; single lab\",\n      \"pmids\": [\"33508319\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ATGL and CGI-58 are co-resident on lipid droplets in rat hepatic stellate cells (HSC-T6). Rat ATGL co-activated by rat CGI-58 efficiently hydrolyzes both triacylglycerols and retinyl esters in vitro.\",\n      \"method\": \"LD proteomics, LD isolation, in vitro hydrolase activity assay with rATGL and rCGI-58\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro enzymatic reconstitution + LD proteomics; single lab\",\n      \"pmids\": [\"26330055\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PNPLA2/ATGL is the rate-limiting triacylglycerol (TG) lipase that initiates intracellular lipolysis via a patatin-domain catalytic dyad (Ser47/Asp166) requiring a minimal active domain extending to Leu254; its lipase activity is co-activated by CGI-58/ABHD5 (released from perilipin 1 upon β-adrenergic stimulation), inhibited by G0S2 and FSP27, regulated by AMPK-mediated phosphorylation at S406, and modulated post-translationally by S-acylation at Cys15 (by zDHHC11), ubiquitin-proteasomal degradation (via COP1, CUL7FBXW8 E3 ligase, LDAH), and PEDF-driven nuclear import; ATGL delivers lipid ligands to PPAR-α/δ to activate PGC-1α/β and mitochondrial oxidative metabolism, generates FAHFAs via transacylation, controls insulin secretion in β-cells via PPARδ, regulates glucose uptake through TXNIP stability, and when absent causes lethal cardiomyopathy, lipid storage myopathy (NLSDM), and impaired thermogenesis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PNPLA2 (desnutrin/ATGL) is the rate-limiting triacylglycerol hydrolase that initiates intracellular lipolysis, mobilizing fatty acids from lipid droplets via a patatin-like domain whose minimal catalytically active fragment extends beyond the canonical patatin region to Leu254 [#0, #1, #4]. Loss-of-function mutations sparing the active site but truncating the hydrophobic domain cause neutral lipid storage disease with myopathy (NLSDM), and ATGL deficiency drives lethal cardiomyopathy that is reversed by PPAR-\\u03b1 agonism, because ATGL-liberated fatty acids serve as ligands that activate PPAR-\\u03b1/\\u03b4 and PGC-1\\u03b1/\\u03b2-driven mitochondrial oxidative metabolism [#1, #2]. Beyond canonical hydrolysis, ATGL catalyzes transacylation reactions that generate FAHFA lipid species and, when HSL is absent, form triglyceride from diacylglycerol [#19, #33]. Its activity is tightly governed: co-activated by CGI-58/ABHD5 through a defined protein interface and inhibited by G0S2, FSP27, and perilipin 1 [#4, #6, #14, #16, #28], activated by AMPK phosphorylation at S406 [#3, #18], and dependent on zDHHC11-mediated S-acylation at Cys15 for catalysis [#20]. ATGL is targeted to lipid droplets through its C-terminal hydrophobic domain and GBF1/Arf1/COPI trafficking, and is restrained by ER-tethering via STX11 and by ubiquitin-proteasomal turnover through CUL7\\u1da0\\u1d47\\u02e3\\u02b7\\u2078, COP1/PEDF, and LDAH [#7, #15, #22, #23, #24, #29]. Transcriptionally, ATGL is induced by FoxO1 (deacetylated by SIRT1) and PPAR\\u03b3 and repressed by insulin via mTORC1\\u2013Egr1 signaling [#8, #9, #10, #11]. Through these outputs ATGL links lipolysis to oxidative metabolism via SIRT1\\u2013PGC-1\\u03b1, controls glucose-stimulated insulin secretion via PPAR\\u03b4 in \\u03b2-cells, and regulates adipocyte glucose uptake by promoting TXNIP degradation [#12, #13, #35].\"\n,\n  \"teleology\": [\n    {\n      \"year\": 2004,\n      \"claim\": \"Established that PNPLA2 encodes a patatin-domain protein with intrinsic triglyceride hydrolase activity, defining the gene product as a lipase.\",\n      \"evidence\": \"Ectopic overexpression with TG hydrolysis assay and EGFP localization in transfected cells\",\n      \"pmids\": [\"15337759\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish in vivo physiological role\", \"Catalytic residues and regulators unidentified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed PNPLA2 is the rate-limiting TG hydrolase in vivo and that its loss causes a human disease, connecting biochemistry to pathology.\",\n      \"evidence\": \"Patient mutation analysis (NLSDM) plus siRNA knockdown with lipid accumulation; insulin/TNF-\\u03b1 promoter regulation by reporter assay\",\n      \"pmids\": [\"17187067\", \"16705060\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream metabolic consequences of fatty-acid liberation not defined\", \"Co-activators and inhibitors not yet identified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified transcriptional control of ATGL by FoxO1, explaining hormonal regulation of lipolytic capacity.\",\n      \"evidence\": \"ChIP, luciferase reporter, siRNA knockdown and lipolysis assay in adipocytes\",\n      \"pmids\": [\"19297333\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address post-translational regulation\", \"Interplay with other transcription factors unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined direct protein inhibitors (G0S2, UBXD8) and the C-terminal LD-targeting domain, establishing that ATGL activity and localization are governed by distinct interactions.\",\n      \"evidence\": \"Co-IP, direct binding, domain deletion mutagenesis and LD morphology assays\",\n      \"pmids\": [\"20676045\", \"23297223\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of inhibitor binding not resolved\", \"Single-lab Co-IP for some interactions\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Connected ATGL-derived lipid ligands to PPAR/PGC-1\\u03b1-driven mitochondrial metabolism and defined AMPK phosphorylation at S406 as an activating modification, explaining the cardiomyopathy and thermogenic phenotypes.\",\n      \"evidence\": \"Atgl-KO and adipose-specific KO mice, mitochondrial respiration, PPAR-\\u03b1 agonist rescue, phosphosite mutagenesis and kinase assay\",\n      \"pmids\": [\"21857651\", \"21641555\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the specific ligand lipid species not defined\", \"How phosphorylation alters catalysis mechanistically unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Mapped the minimal catalytic domain to Leu254 and showed it suffices for CGI-58 co-activation and G0S2 inhibition, localizing regulation to a defined region.\",\n      \"evidence\": \"Truncation mutagenesis, in vitro lipase assay, binding assay, homology modeling\",\n      \"pmids\": [\"22039468\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No experimental crystal structure\", \"Role of the C-terminal region in vivo not fully resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Linked SIRT1 deacetylation of FoxO1 to ATGL transcription, integrating energy/NAD+ status with lipolytic gene expression.\",\n      \"evidence\": \"shRNA knockdown, lipolysis and gene expression assays in adipocytes\",\n      \"pmids\": [\"21743036\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct demonstration of FoxO1 acetylation at the ATGL promoter limited\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified GBF1/Arf1/COPI trafficking as a route delivering ATGL to lipid droplets, defining a transport mechanism.\",\n      \"evidence\": \"Yeast two-hybrid, Co-IP, direct binding and localization of GBF1 domain fragments\",\n      \"pmids\": [\"21789191\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological contribution of this route versus C-terminal targeting unquantified\", \"Single-lab interaction data\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Distinguished perilipin 1 as a direct in vitro inhibitor and obligate translocation factor versus FSP27's constitutive restriction, refining the LD-surface regulatory hierarchy.\",\n      \"evidence\": \"In vitro TAG hydrolase assay, siRNA, LD translocation imaging\",\n      \"pmids\": [\"23204327\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of perilipin1\\u2013ATGL inhibition not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Extended the regulatory network with FSP27 direct binding, mTORC1\\u2013Egr1 insulin repression, and a \\u03b2-cell PPAR\\u03b4 lipolytic-signaling axis controlling insulin secretion.\",\n      \"evidence\": \"Co-IP/domain mapping, yeast screen with promoter binding, \\u03b2-cell-specific KO with PPAR\\u03b4 agonist rescue and contraction-state muscle Co-IP\",\n      \"pmids\": [\"24627478\", \"23858058\", \"24268737\", \"23408028\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific differences in regulator usage not fully mapped\", \"Some interaction data from single labs\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Established SIRT1 as a node downstream of ATGL lipolysis driving PGC-1\\u03b1/PPAR-\\u03b1 oxidative transcription independent of NAD+, clarifying signal-to-transcription coupling.\",\n      \"evidence\": \"ATGL gain/loss, SIRT1 deacetylase activity assay, \\u03b2-adrenergic stimulation\",\n      \"pmids\": [\"25614670\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which a lipid product activates SIRT1 unresolved\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Provided in vivo proof that AMPK phosphorylates and activates ATGL at S406 and defined reciprocal ATGL-dependent G0S2 protein stabilization, closing loops in activity regulation.\",\n      \"evidence\": \"Adipose-specific AMPK double-KO mice, phosphorylation and TAG hydrolase assays; G0S2 K25 ubiquitination mutagenesis with Atgl-KO tissue\",\n      \"pmids\": [\"27185873\", \"27248498\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether AMPK acts directly on ATGL in vivo versus via other kinases not fully excluded\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined ubiquitin-proteasomal turnover (LDAH-enhanced) and a tumor-suppressive epistasis with HSL whose dual loss causes liposarcoma, linking lipolytic capacity to proliferation control.\",\n      \"evidence\": \"Ubiquitination/pulse-chase assays; adipose-specific ATGL/HSL double-KO mouse with tumor histology\",\n      \"pmids\": [\"28578400\", \"28459858\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking lipid accumulation to tumorigenesis not defined\", \"E3 ligase for LDAH-driven turnover not identified here\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Revealed ATGL transacylase activity (DG-to-TG when HSL is absent), nuclear COP1/PEDF degradation, and tissue-specific intestinal substrate pools, broadening its enzymatic and regulatory repertoire.\",\n      \"evidence\": \"Radiolabeled DG transacylation with inhibitor control; Co-IP and nuclear fractionation; intestine-specific double KO\",\n      \"pmids\": [\"31035700\", \"30926171\", \"31412256\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological significance of transacylase activity under normal HSL unclear\", \"Nuclear degradation pathway from single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Connected ATGL lipolysis to glucose handling by showing it promotes TXNIP degradation to enhance GLUT1-mediated glucose uptake, expanding its role beyond fatty-acid metabolism.\",\n      \"evidence\": \"Knockdown/overexpression, TXNIP stability and GLUT1 surface assays in mouse and human adipocytes\",\n      \"pmids\": [\"33508319\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signal linking lipolysis to TXNIP turnover not fully defined\", \"Single-lab mechanism\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established ATGL as the principal biosynthetic enzyme for FAHFAs via transacylation, identifying a signaling-lipid output of the lipase.\",\n      \"evidence\": \"Recombinant ATGL in vitro transacylation, catalytic-dead mutant, atglistatin, adipose-specific KO, validated in human tissue\",\n      \"pmids\": [\"35676490\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Regulation of hydrolase-versus-transacylase partitioning unclear\", \"Acceptor/donor specificity in vivo not fully mapped\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified S-acylation at Cys15 by zDHHC11 as essential for catalysis and a Golgi PtdIns4P/CUL7FBXW8 glucose-sensing ubiquitylation circuit, plus a PNPLA3(148M) mechanism that sequesters ABHD5, defining post-translational and competitive controls on lipolysis.\",\n      \"evidence\": \"C15 mutagenesis with acylation/lipolysis assays; PtdIns4P/CUL7FBXW8 assembly and ubiquitylation assays with human liver; NanoBiT and purified-protein hydrolysis with Atgl-KO mice\",\n      \"pmids\": [\"39143266\", \"38561547\", \"39550037\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Cys15 acylation alters the catalytic mechanism not structurally defined\", \"Interplay among competing ubiquitin ligases not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"An integrated structural and quantitative model of how the multiple competing co-activators, inhibitors, and post-translational modifications set ATGL output in each tissue remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No experimental high-resolution structure of full-length ATGL or its regulatory complexes\", \"Relative in vivo weighting of CGI-58, G0S2, perilipin1, FSP27, acylation, and degradation not quantified\", \"Determinants of hydrolase-versus-transacylase activity unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1, 4, 16, 36]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [19, 33]},\n      {\"term_id\": \"GO:0016298\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005811\", \"supporting_discovery_ids\": [5, 7, 16, 20, 36]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [29]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 2, 19]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 12, 13, 35]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [20, 22, 23, 24]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ABHD5\", \"G0S2\", \"CIDEC\", \"PLIN1\", \"UBXD8\", \"GBF1\", \"STX11\", \"PNPLA3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}